[ad_1]
In February, began Alzinovas Toxicological experiments with ALZ-101 on macaques. The company now presents the results, showing that the monkeys responded to the vaccination by increasing the number of antibodies according to the number of doses, while displaying normal behavior and another freshness throughout the entire period. study.
When macaques internal organs were examined, we could not see any side effects of the drug, quite in line with previous studies on mice, rabbits and macaroons.
"With these good results from the GLP toxicology study at the back, we are confident that the safety of ALZ-101 is very good." The study is one of the cornerstones of the next clinical study on humans.We intend to start this study as soon as the clinical material is delivered and to have received the approval of the application. clinical trial to submit to the authorities as soon as all preclinical data have been compiled, Per Wester, CEO of Alzinovain a press release.
[ad_2]
Source link
